So in terms of subgroup analysis, we do not have the full data as of now, but looking from an outset, like there was nothing like that, but I would like to mention one thing specifically, this data may be sort of may be affected by the treatment as well. So we observed that patients were having a treatment response to the systemic therapy to start with. So those patients fared better in terms of weight gain as well...
So in terms of subgroup analysis, we do not have the full data as of now, but looking from an outset, like there was nothing like that, but I would like to mention one thing specifically, this data may be sort of may be affected by the treatment as well. So we observed that patients were having a treatment response to the systemic therapy to start with. So those patients fared better in terms of weight gain as well. So we can’t be sure about that. But again, those patients who had progressed after three months of systemic therapy, most of them had done worse in case of weight gain and appetite complaint and all those things. So we can’t really opine about the drugs per se, but so it is like that, that patients who have responded to the systemic therapy, they are found to be doing much better in terms of anorexia and weight gain as well. So how much did these megestrol acetate and like in terms of that, both the drugs, whether it’s olanzapine or megestrol acetate, did actually contribute to weight gain. So, but there’s no way you can find it out. There’s so many sort of confounding factors in terms of treatment response or treatment progression. So that was our take.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
